{"pub": "wsj", "url": "https://marketwatch.com/story/biogens-stock-surge-increases-value-of-recent-stock-repurchased-by-over-700-million-2019-10-22?mod=rsswn", "downloaded_at": "2019-10-22 15:34:11.238011+00:00", "title": "Biogen's stock surge increases value of recent stock repurchased by over $700 million", "language": "en", "text": "Biogen Inc. BIIB, +26.28% did a good job buying low, as the biotechnology company's stock rally on Tuesday has boosted the value of the shares repurchased over the past six months by about $708.6 million. The company said it bought back 3.1 million shares for a total value of approximately $718 million, which implies an average price paid of $231.61 per share. With the stock soaring 27% to $283.45, after the company said it would pursue regulatory approval of its treatment for Alzheimer's disease and following a big earnings beat, it would now take $878.7 million to buy back 3.1 million shares, or about $161.7 million more than Biogen paid. During the second quarter, the company had bought 10.4 million shares for about $2.4 billion, implying an average price paid of $230.77 per share. At current prices, it would cost $2.95 billion to buyback 10.4 million shares. The stock had plunged in March after the company said it would discontinue Phase 3 trials of its Alzheimer's drug. The stock has still lost 5.6% year to date, while the Dow Jones Industrial Average DJIA, +0.14% has gained 15.2%.", "description": "Biogen Inc. did a good job buying low, as the biotechnology company's stock rally on Tuesday has boosted the value of the shares repurchased over the past...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-22"}